Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2025 10:43 ET | Source: Research and Markets

2025 Global Research: Hematology Analyzers and Reagents Market Projected to Reach $3.28 Billion by 2030, Driven by Technological Advances and Rising Demand for Diagnostic Precision

Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Hematology Analyzers and Reagents Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F" report has been added to ...
June 17, 2024 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and...
June 12, 2023 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months ...
April 24, 2023 13:00 ET | Source: DelveInsight Business Research LLP

DelveInsight Evaluates a Robust Waldenstrom’s Macroglobulinemia Pipeline as 20+ Influential Pharma Players to Set Foot in the Domain

New York, USA, April 24, 2023 (GLOBE NEWSWIRE) -- DelveInsight Evaluates a Robust Waldenstrom’s Macroglobulinemia Pipeline as 20+ Influential Pharma Players to Set Foot in the Domain The prevalence...
October 27, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) --...
June 22, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia

WORCESTER, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
June 08, 2021 07:58 ET | Source: Research and Markets

Global Waldenstrom Macroglobulinemia (WM) Market Spotlight Report 2021: Bristol Myers Squibb, Johnson & Johnson, and Takeda Lead Industry Sponsors with the Highest Overall Number of Clinical Trials

Dublin, June 08, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Waldenstrom Macroglobulinemia (WM)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers...